Sign up for news & promotions:
CD369 Primary Antibody
|Aliases||CLEC7A; BGR; CANDF4; SCARE2; DECTIN1; CLECSF12|
|Formulation||Purified antibody in PBS with 0.05% sodium azide|
|IHC_P (Immunohistochemistry)||Purified recombinant fragment of human CD315 (AA: extra 46-221) expressed in E. Coli.|
|FCM (Flow Cytometry)||1/200 - 1/400|
|(AA: extra 66-247) expressed in E. Coli.|
Figure 1: Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Figure 2: Western blot analysis using CD369 mAb against human CD369 (AA: extra 66-247) recombinant protein. (Expected MW is 46.5 kDa)
Figure 3: Western blot analysis using CD369 mAb against HEK293 (1) and CD369 (AA: extra 66-247)-hIgGFc transfected HEK293 (2) cell lysate.
Figure 4: Flow cytometric analysis of HL-60 cells using CD369 mouse mAb (green) and negative control (red).
|Tissue Array Results|
|View Full Documents|
This gene encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. The encoded glycoprotein is a small type II membrane receptor with an extracellular C-type lectin-like domain fold and a cytoplasmic domain with an immunoreceptor tyrosine-based activation motif. It functions as a pattern-recognition receptor that recognizes a variety of beta-1,3-linked and beta-1,6-linked glucans from fungi and plants, and in this way plays a role in innate immune response. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. This gene is closely linked to other CTL/CTLD superfamily members on chromosome 12p13 in the natural killer gene complex region.
|References (references)||1.Br J Cancer. 2011 Feb 1;104(3):496-504.
2.J Proteomics. 2009 Nov 2;73(1):93-102.